Design, synthesis, and evaluation of stable and taste-free erythromycin proprodrugs.
Pranab K Bhadra, Gareth A Morris, Jill Barber
Index: J. Med. Chem. 48(11) , 3878-84, (2005)
Full Text: HTML
Abstract
Erythromycin A is normally formulated for children as its 2'-ethyl succinate, a taste-free prodrug. Unfortunately, the prodrug hydrolyzes at a measurable rate in the medicine bottle, leading to the vile-tasting erythromycin. We have prepared derivatives of erythromycin B as putative paediatric prodrugs, taking advantage of the much improved acid stability of erythromycin B relative to erythromycin A. Thus, erythromycin B enol ether ethyl succinate is very poorly soluble in water, and its hydrolysis is undetectable in conditions resembling the medicine bottle. In acid, however, it converts rapidly to erythromycin B 2'-ethyl succinate, and this is in turn hydrolyzed to erythromycin B in neutral and basic conditions. Derivatives of erythromycin B enol ether are therefore proposed as taste-free proprodrugs of erythromycin B.
Related Compounds
Related Articles:
2007-01-01
[Rapid Commun. Mass Spectrom. 21(2) , 237-46, (2007)]
2000-02-10
[J. Med. Chem. 43(3) , 467-74, (2000)]
An abiotic strategy for the enantioselective synthesis of erythromycin B.
2003-07-21
[Angew. Chem. Int. Ed. Engl. 42(28) , 3278-81, (2003)]
2002-09-03
[Biochemistry 41(35) , 10827-33, (2002)]
1990-05-01
[J. Antibiot. 43(5) , 544-9, (1990)]